-- 阿布扎比伊斯兰银行(ADX:ADIB)周三公布的第一季度业绩超出预期,主要得益于资产负债表扩张和关键业务板块持续的客户增长。 截至3月31日的三个月,归属于银行股东的净利润同比增长至17.1亿迪拉姆,高于去年同期的16.2亿迪拉姆;每股收益(EPS)也从0.417迪拉姆增至0.444迪拉姆。FactSet调查的分析师此前预期净利润为16.5亿迪拉姆。 与此同时,该行的净减值准备金同比增加50%,达到1.58亿迪拉姆,但风险成本保持在0.48%的“相当稳定”,与此前的预期一致。不良资产率进一步改善至2.6%,创下该伊斯兰银行的历史新低。 凭借新增的6.6万名客户和持续增长的业务量,该集团的营业收入从去年同期的41.2亿迪拉姆增至47.3亿迪拉姆。其中,融资收入增长17%至20亿迪拉姆,主要得益于融资额的增长和可持续的回报。非融资收入小幅增长4%至12亿迪拉姆,主要得益于投资收益增长10%。 在资产负债表方面,总资产增长18%至2870亿迪拉姆,主要得益于零售银行和企业银行业务融资的增长以及集团投资组合的扩张。客户存款增长20%至2390亿迪拉姆,净资产收益率为27.1%。 集团首席执行官穆罕默德·阿卜杜勒巴里表示:“我们将继续专注于‘2035愿景’中的各项战略重点。” “我们强劲的资产负债表、多元化的运营模式和健康的业务储备使我们能够继续支持我们的客户和更广泛的经济,同时专注于可持续的长期价值创造。”
Related Articles
Berenberg Adjusts Estimates for Galp Energia After 'Solid' Q1 Results; Hold Rating Maintained
Berenberg updated its earnings forecasts for Galp Energia (GALP.LS) after the Portuguese energy company reported its first-quarter results."Galp reported a solid set of results for Q126 on 27 April from an operational point of view, and beat consensus EBITDA expectations, although this was offset by some cash flow adjustments in the period. Delivery of the important Bacalhau project (Brazil) appears to be ahead of expectations, and, after a strong Q1 in the refining business, Galp is moving towards confirming the terms of its downstream merger with Moeve. In the earnings call, the company indicated that its 2026 guidance is now likely out of date given the macro backdrop, and that it may update its FY26 outlook in the Q2 results. We leave our Hold rating and EUR20 price target unchanged," the research firm said Wednesday.Against this backdrop, the research firm increased its 2026 EBITDA assumption by 3%, while cutting its cash flow from operations and free cash flow estimates by 4% and 3%, respectively, to account for a recent 320 million-euro renewable acquisition and other liquidity adjustments.Meanwhile, analysts maintained their share repurchase projection for 2026 at 250 million euros, while boosting their 2027 forecast to 455 million euros, which is 10% above consensus. Berenberg's EPS estimates for 2026 through 2028 were also revised upwards.
Henlius Biotech Doses First Patient in Lung Cancer Drug Trial in China
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX3901 in mainland China, according to a Thursday Hong Kong bourse filing.The drug is being tested for the treatment of patients with advanced small-cell lung cancer or neuroendocrine carcinoma.
BP Confirms Preliminary Offshore Exploration Agreement With Venezuela
BP (BP.L) entered into a memorandum of understanding with the Bolivarian Republic of Venezuela to establish "potential areas for co‑operation in material offshore gas and future exploration," according to a statement sent toon Thursday.Venezuela's Acting President Delcy Rodríguez announced in a Wednesday signing event its offshore natural gas exploration deal with the British oil major, which covers the Deltana Platform, an oil and natural gas reservoir in the nation's eastern waters, according to a same-day report from Bloomberg News.BP Executive Vice President William Lin also said the company plans to launch a permanent regional office in Caracas, Venezuela.